Finanzen von Ultragenyx Pharmaceutical Inc (RARE)RAREUltragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. (RARE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Crysvita royalty revenue, accounting for 47.7% of total sales, equivalent to $102.00M. Other significant revenue streams include Crysvita and Dojolvi. Understanding this composition is critical for investors evaluating how RARE navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Ultragenyx Pharmaceutical Inc. maintains a gross margin of 84.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -35.05%, while the net margin is -42.99%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RARE converts its operational activities into shareholder value.

In the context of the broader market, RARE competes directly with industry leaders such as ETON and PCRX. With a market capitalization of $1.47B, it holds a significant position in the sector. When comparing efficiency, RARE's gross margin of 84.11% stands against ETON's 67.61% and PCRX's 69.60%. Such benchmarking helps identify whether Ultragenyx Pharmaceutical Inc. is trading at a premium or discount relative to its financial performance.

Ultragenyx has shown fluctuating revenue, with Q2 2026 revenue at $214 million and a gross margin of 84.11%. However, it continues to report negative net income, with the latest figure at -92 million.